Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.65 |
| ▸ | CNR2 | P34972 | 5/20 | 0.65 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620904 | 0.90 | CNR2 (0.67) | CNR1CNR2GAA | |
| SCHEMBL1621041 | 0.89 | CNR2 (0.66) | CNR1CNR2GAA | |
| SCHEMBL1621150 | 0.89 | CNR2 (0.66) | CNR1CNR2GAA | |
| SCHEMBL12752445 | 0.89 | CNR2 (0.66) | CNR1CNR2GAA | |
| SCHEMBL1621327 | 0.87 | CNR1 (0.63) | CNR1CNR2NAMPTMAOBMAOA | |
| SCHEMBL13908529 | 0.86 | CNR1 (0.62) | CNR1CNR2NAMPTDRD2 | |
| SCHEMBL1620940 | 0.86 | CNR1 (0.71) | CNR1CNR2HRH3NAMPTMAPT | |
| SCHEMBL1620554 | 0.84 | CNR2 (0.62) | CNR1CNR2MAOBMAOARIPK1 | |
| SCHEMBL1621326 | 0.83 | CNR2 (0.61) | CNR1CNR2NAMPTMAOBMAOA | |
| SCHEMBL1621256 | 0.82 | CNR2 (0.60) | CNR1CNR2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS, B.V. | 2011-06-30 | — | — | US | disclosed |
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS, B.V. | 2011-06-30 | — | — | US | disclosed |
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS, B.V. | 2011-06-30 | — | — | US | disclosed |
| US-7928134-B2 | 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-04-19 | — | — | US | disclosed |
| US-7928134-B2 | 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-04-19 | — | — | US | disclosed |
| US-7928134-B2 | 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-04-19 | — | — | US | disclosed |
| WO-2009037244-A2 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. | 2009-03-26 | — | — | US | disclosed |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. | 2009-03-26 | — | — | US | disclosed |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | CNR1, CNR2, HTR5A | CNR1 1/4885CNR2 2/4885DHODH 1601/4885 |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | CNR1, CNR2, HTR5A | CNR1 1/4885CNR2 2/4885DHODH 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.